Want to see IN:PPLPHARMA full AI Analyst Report?
Top Page
Piramal Pharma Limited
(PPLPHARMA)
Select Model
Select Model
Rating:56Neutral
Price Target:
₹240.00
▲(24.58% Upside)
Action:Reiterated
Date:10/29/26
The score is primarily driven by mixed financial performance: strong revenue growth and improving cash generation are offset by recurring loss years and inconsistent returns. Technically, the stock is in an uptrend but appears overbought, while valuation is constrained by a negative P/E and a low dividend yield.
Positive Factors
Revenue Scale-Up
The substantial multi-year revenue expansion indicates that Piramal Pharma has increased its commercial scale across CDMO, hospital generics, and consumer healthcare. A larger revenue base can support operating leverage, broader customer relationships, and continued investment in capabilities over the next several quarters.
Negative Factors
Recurring Profitability Volatility
Repeated losses and limited profits across recent years reduce confidence that revenue growth is translating into durable earnings. The return to a bottom-line loss in FY2026 suggests pressure below operating profit, which could constrain reinvestment capacity and make future results more dependent on successful execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Scale-Up
The substantial multi-year revenue expansion indicates that Piramal Pharma has increased its commercial scale across CDMO, hospital generics, and consumer healthcare. A larger revenue base can support operating leverage, broader customer relationships, and continued investment in capabilities over the next several quarters.
Read all positive factors
Piramal Pharma Limited (PPLPHARMA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹318.26B
Dividend Yield0.06%
Average Volume (3M)466.79K
Price to Earnings (P/E)―
Beta (1Y)1.21
Revenue Growth9.43%
EPS Growth-767.49%
CountryIN
Employees7,120
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-2.37
Shares Outstanding1,331,348,100
10 Day Avg. Volume836,545
30 Day Avg. Volume466,790
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.22
Price to Sales (P/S)2.04
P/FCF Ratio35.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.42
Revenue Forecast (FY)₹103.33B
Piramal Pharma Limited Business Overview & Revenue Model
Company Description
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facili...
How the Company Makes Money
Piramal Pharma Limited makes money through three main revenue streams. (1) CDMO services: It earns service and manufacturing revenue by partnering with pharmaceutical and biotechnology companies to develop processes, scale up, and manufacture acti...
Piramal Pharma Limited Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
58
Neutral
Cash Flow
66
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 92.05B | 88.69B | 90.61B | 81.06B | 70.32B | 64.72B |
| Gross Profit | 32.91B | 23.83B | 54.89B | 48.48B | 40.32B | 37.91B |
| EBITDA | 10.81B | 9.96B | 16.49B | 13.67B | 8.94B | 12.60B |
| Net Income | -3.14B | -3.26B | 911.30M | 178.20M | -1.86B | 3.76B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 179.65B | 156.78B | 153.12B | 145.23B | 127.97B |
| Cash, Cash Equivalents and Short-Term Investments | 13.55B | 13.55B | 5.21B | 5.02B | 6.60B | 3.79B |
| Total Debt | 0.00 | 56.75B | 48.56B | 47.10B | 56.37B | 41.28B |
| Total Liabilities | -81.63B | 98.02B | 75.52B | 74.00B | 77.49B | 61.00B |
| Stockholders Equity | 81.63B | 81.63B | 81.25B | 79.11B | 67.73B | 66.97B |
Cash Flow | ||||||
| Free Cash Flow | 4.57B | 5.10B | 2.28B | 2.92B | -4.81B | -1.23B |
| Operating Cash Flow | 8.90B | 14.00B | 8.92B | 10.05B | 4.84B | 7.66B |
| Investing Cash Flow | -4.68B | -8.69B | -4.77B | -4.34B | -13.39B | -18.12B |
| Financing Cash Flow | -3.61B | 2.57B | -4.41B | -4.22B | 8.18B | 7.94B |
Piramal Pharma Limited Technical Analysis
Positive
192.65
Price Trends
207.81
Positive
194.94
Positive
177.10
Positive
Market Momentum
4.75
Negative
73.03
Negative
92.21
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PPLPHARMA, the sentiment is Positive. The current price of 192.65 is below the 20-day moving average (MA) of 201.72, below the 50-day MA of 207.81, and above the 200-day MA of 177.10, indicating a bullish trend. The MACD of 4.75 indicates Negative momentum. The RSI at 73.03 is Negative, neither overbought nor oversold. The STOCH value of 92.21 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:PPLPHARMA.
Piramal Pharma Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹130.28B | 46.20 | ― | 0.61% | 4.02% | -12.81% | |
56 Neutral | ₹318.26B | -151.42 | ― | 0.06% | 9.43% | -767.49% | |
56 Neutral | ₹22.76B | 33.34 | ― | 0.11% | -20.86% | -34.51% | |
56 Neutral | ₹162.52B | 86.98 | ― | 0.31% | -5.99% | -60.30% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | ₹89.05B | 25.14 | ― | 0.89% | 15.41% | 21.76% | |
49 Neutral | ₹573.10B | 103.47 | ― | 0.14% | 9.83% | 5.07% |
* General Sector Average
IN:PPLPHARMA
Piramal Pharma Limited
239.05
39.30
19.67%
IN:BIOCON
Biocon Limited
352.00
-19.56
-5.26%
IN:CONCORDBIO
Concord Biotech Ltd.
1,245.30
-188.76
-13.16%
IN:DCAL
Dishman Carbogen Amcis Ltd.
145.15
-146.60
-50.25%
IN:JUBLINGREA
Jubilant Ingrevia Ltd.
559.05
-125.35
-18.32%
IN:SYNGENE
Syngene International Ltd.
402.60
-245.86
-37.91%
Piramal Pharma Limited Corporate Events
Piramal Pharma Delivers Strong H1FY27 Performance and Upgrades Full-Year Outlook
Oct 27, 2026
Piramal Pharma Limited reported strong consolidated results for the second quarter and first half of FY27, with revenue from operations rising 28% year-on-year in Q2 and 23% in H1, driven by broad-based growth across CDMO, CHG and consumer healthc...
Piramal Pharma Posts Strong H1 FY27 Growth and Upgrades Full-Year Outlook
Oct 27, 2026
Piramal Pharma reported robust unaudited consolidated results for the second quarter and first half of FY27, with revenue from operations rising 28% year-on-year in Q2 and 23% in H1, driven by broad-based growth across CDMO, CHG and consumer healt...
Piramal Pharma Delivers Strong H1 FY27 and Upgrades Full-Year Outlook
Oct 27, 2026
Piramal Pharma Limited has reported strong financial performance for the second quarter and first half of FY27, with consolidated revenue from operations rising 28% year-on-year in Q2 and 23% in H1, driven by broad-based growth across CDMO, CHG, a...
Piramal Pharma Appoints Viral Gandhi as Chief Technology Officer
Sep 30, 2026
Piramal Pharma Limited has announced that its Board of Directors, following the recommendation of the Nomination and Remuneration Committee, has approved the appointment of Viral Gandhi as Chief Technology Officer and Senior Management Personnel e...
Piramal Pharma to Appeal GST Order Confirming Rs 4.06 Crore Input Tax Credit Demand
Sep 29, 2026
Piramal Pharma Limited has disclosed that it received an Order-in-Original from the Additional Commissioner, CGST Central Excise, Mumbai East, following a GST audit for financial years 2020-21 to 2022-23. The order disputes the eligibility of cer...
Piramal Pharma earns ‘Leader’ ESG rating from independent assessor
Sep 18, 2026
Piramal Pharma Limited has received an Environment, Social and Governance rating of 67.1, placing it in the ‘Leader’ ESG band according to Niche Ninety Nine Capability and Certifications. The rating was communicated to the company by B...
Piramal Pharma Addresses FDA Observations at Morpeth Facility
Sep 14, 2026
Piramal Pharma Limited has announced that the U.S. FDA conducted a Good Manufacturing Practices inspection at its Morpeth, U.K. facility from September 3 to September 11, 2026. The inspection resulted in a Form 483 containing seven observations, w...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.